Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.61 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | GNA15 | P30679 | 1/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854760 | 0.88 | PLK1 (0.59) | FFAR1FFAR4PLK1 | |
| SCHEMBL11835323 | 0.88 | PLK1 (0.59) | FFAR1FFAR4PLK1 | |
| SCHEMBL3426470 | 0.87 | PLK1 (0.61) | FFAR1PLK1 | |
| SCHEMBL12721515 | 0.87 | LTA4H (0.62) | FFAR1LTA4H | |
| SCHEMBL16558294 | 0.87 | LTA4H (0.62) | FFAR1LTA4H | |
| SCHEMBL4546800 | 0.87 | LTA4H (0.62) | FFAR1LTA4H | |
| SCHEMBL15312061 | 0.87 | LTA4H (0.62) | FFAR1LTA4H | |
| SCHEMBL12056748 | 0.87 | LTA4H (0.62) | FFAR1LTA4H | |
| SCHEMBL855509 | 0.85 | MAPT (0.65) | LTA4H | |
| SCHEMBL2453789 | 0.85 | LTA4H (0.61) | FFAR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1308438-B9 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-28 | — | — | EP | disclosed |
| EP-1308438-B1 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7105567-B2 | 3-substituted urea derivatives and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-09-12 | — | — | US | disclosed |
| US-20030207939-A1 | Novel 3-substituted urea derivatives and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1308438-A1 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207939-A1 | Novel 3-substituted urea derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | FFAR1 138/4885FFAR4 216/4885CACNA1B 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.